PT2854814T - Moduladores de recetores de glucocorticoides de azadecalina fundida com heteroaril-cetona - Google Patents

Moduladores de recetores de glucocorticoides de azadecalina fundida com heteroaril-cetona

Info

Publication number
PT2854814T
PT2854814T PT137934170T PT13793417T PT2854814T PT 2854814 T PT2854814 T PT 2854814T PT 137934170 T PT137934170 T PT 137934170T PT 13793417 T PT13793417 T PT 13793417T PT 2854814 T PT2854814 T PT 2854814T
Authority
PT
Portugal
Prior art keywords
heteroaryl
receptor modulators
glucocorticoid receptor
fused azadecalin
ketone fused
Prior art date
Application number
PT137934170T
Other languages
English (en)
Inventor
Ray Nicholas
Hunt Hazel
Johnson Tony
Walters Iain
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Publication of PT2854814T publication Critical patent/PT2854814T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53831,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
PT137934170T 2012-05-25 2013-05-24 Moduladores de recetores de glucocorticoides de azadecalina fundida com heteroaril-cetona PT2854814T (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261651669P 2012-05-25 2012-05-25
US201261691083P 2012-08-20 2012-08-20
US201261715907P 2012-10-19 2012-10-19
US201361759520P 2013-02-01 2013-02-01
US201361781629P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
PT2854814T true PT2854814T (pt) 2018-03-15

Family

ID=49624542

Family Applications (4)

Application Number Title Priority Date Filing Date
PT137934170T PT2854814T (pt) 2012-05-25 2013-05-24 Moduladores de recetores de glucocorticoides de azadecalina fundida com heteroaril-cetona
PT211546650T PT3851107T (pt) 2012-05-25 2013-05-24 Moduladores de recetores de glucocorticoides de azadecalina fundida com heteroaril-cetona
PT191888858T PT3590517T (pt) 2012-05-25 2013-05-24 Moduladores de recetores de glucocorticoides de azadecalina fundida com heteroaril-cetonas
PT181542564T PT3338781T (pt) 2012-05-25 2013-05-24 Moduladores de recetores de glucocorticoides de azadecalina fundida com heteroaril-cetonas

Family Applications After (3)

Application Number Title Priority Date Filing Date
PT211546650T PT3851107T (pt) 2012-05-25 2013-05-24 Moduladores de recetores de glucocorticoides de azadecalina fundida com heteroaril-cetona
PT191888858T PT3590517T (pt) 2012-05-25 2013-05-24 Moduladores de recetores de glucocorticoides de azadecalina fundida com heteroaril-cetonas
PT181542564T PT3338781T (pt) 2012-05-25 2013-05-24 Moduladores de recetores de glucocorticoides de azadecalina fundida com heteroaril-cetonas

Country Status (22)

Country Link
EP (5) EP3851107B1 (pt)
JP (1) JP6172871B2 (pt)
KR (1) KR102062640B1 (pt)
CN (1) CN104619328B (pt)
AU (1) AU2013266110C1 (pt)
CA (1) CA2872260C (pt)
CL (1) CL2014003173A1 (pt)
DK (4) DK2854814T3 (pt)
ES (4) ES2753816T3 (pt)
HK (2) HK1208818A1 (pt)
IL (1) IL235868A (pt)
MX (1) MX365423B (pt)
MY (1) MY172739A (pt)
NZ (1) NZ701469A (pt)
PE (1) PE20150352A1 (pt)
PH (1) PH12014502584B1 (pt)
PL (4) PL3338781T3 (pt)
PT (4) PT2854814T (pt)
RU (1) RU2639867C2 (pt)
SG (1) SG11201407682TA (pt)
WO (1) WO2013177559A2 (pt)
ZA (1) ZA201408182B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
CA2931302C (en) 2013-11-25 2021-12-07 Corcept Therapeutics, Inc. Octahydro fused azadecalin glucocorticoid receptor modulators
AU2016226451B2 (en) * 2015-03-02 2019-12-19 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonist and somatostatin analogues to treat ACTH-secreting tumors
WO2016160969A1 (en) * 2015-03-30 2016-10-06 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency
KR20240014584A (ko) * 2015-05-18 2024-02-01 코어셉트 쎄라퓨틱스 인코포레이티드 쿠싱 증후군을 진단하고 이에 대한 치료를 평가하는 방법
EP3335043B1 (en) * 2015-08-13 2021-03-31 Corcept Therapeutics, Inc. Method for differentially diagnosing acth-dependent cushing's syndrome
EP3423453A4 (en) * 2016-03-01 2019-11-06 Corcept Therapeutics, Inc. USE OF GLUCOCORTICOID RECEPTOR MODULATORS TO POTENTIATE CONTROL POINT INHIBITORS
US9943505B2 (en) 2016-09-09 2018-04-17 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat pancreatic cancer
JP2020515563A (ja) * 2017-03-31 2020-05-28 コーセプト セラピューティクス, インコーポレイテッド 子宮頸がんを処置するためのグルココルチコイドレセプターモジュレーター
EP3641780A4 (en) * 2017-06-20 2021-02-24 Corcept Therapeutics, Inc. TREATMENT METHODS OF NEURO-EPITHELIAL TUMORS USING SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS
AU2019261274B2 (en) * 2018-04-23 2021-10-28 Corcept Therapeutics, Inc. Methods of preparing regioselective N-alkyl triazoles
MX2021005438A (es) * 2018-11-09 2021-06-15 Corcept Therapeutics Inc Metodos para reducir el tama?o de tumores hipofisarios.
EP3897589A4 (en) * 2018-12-19 2022-10-12 Corcept Therapeutics Incorporated PHARMACEUTICAL FORMULATIONS CONTAINING A RELACORILANT, AN AZADECALIN COMPOUND FUSED WITH A HETEROARYL KETONE
WO2020132046A1 (en) 2018-12-19 2020-06-25 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
MX2021007402A (es) 2018-12-20 2021-07-15 Corcept Therapeutics Inc Metodos para la toma de imagenes y el tratamiento de tumores positivos para el receptor de somatostatina.
MX2021010135A (es) * 2019-02-22 2021-09-23 Corcept Therapeutics Inc Usos terapeuticos de relacorilante, un modulador del receptor de glucocorticoides de azadecalina fusionada con heteroaril-cetona.
AU2020367769B2 (en) * 2019-10-16 2023-10-12 Corcept Therapeutics Incorporated Method of normalizing the neutrophil to lymphocyte ratio in cancer patients with a selective glucocorticoid receptor antagonist
EP4072556A4 (en) 2019-12-11 2024-01-03 Corcept Therapeutics Inc METHOD FOR TREATING ANTIPSYCHOTIC-INDUCED WEIGHT GAIN WITH MIRICORILANT
AU2020408057A1 (en) * 2019-12-21 2022-06-16 Corcept Therapeutics Incorporated Treatment of, and differential diagnosis between, ACTH-Dependent Cushing's syndrome and ACTH-Independent Cushing's syndrome
WO2022134033A1 (en) * 2020-12-25 2022-06-30 Corcept Therapeutics Incorporated Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
CN116829556A (zh) * 2021-02-03 2023-09-29 江苏恒瑞医药股份有限公司 稠合的氮杂三环类衍生物、其制备方法及其在医药上的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
GB8828669D0 (en) * 1988-12-08 1989-01-11 Lilly Industries Ltd Organic compounds
DK1735308T3 (da) * 2004-03-09 2009-01-19 Corcept Therapeutics Inc Kondenserede azadecalinringe som glucocorticoidreceptormodulatorer
US7640389B2 (en) * 2006-02-28 2009-12-29 Freescale Semiconductor, Inc. Non-volatile memory having a multiple block erase mode and method therefor
EP1932843A1 (en) * 2006-12-14 2008-06-18 sanofi-aventis Sulfonyl-phenyl-2H-(1,2,4) oxadiazole-5-one derivatives, processes for their preparation and their use as pharmaceuticals
MX2013002186A (es) 2010-08-27 2013-06-28 Corcept Therapeutics Inc Moduladores de azadecalina de piridil-amina fusionada.

Also Published As

Publication number Publication date
MX2014014239A (es) 2015-08-05
EP3590517B1 (en) 2021-03-17
AU2013266110A1 (en) 2014-11-20
ZA201408182B (en) 2017-09-27
KR102062640B1 (ko) 2020-01-06
RU2639867C2 (ru) 2017-12-25
MX365423B (es) 2019-06-03
CL2014003173A1 (es) 2015-02-27
PL2854814T3 (pl) 2018-07-31
EP3338781B1 (en) 2019-09-11
PH12014502584A1 (en) 2015-01-21
PL3338781T3 (pl) 2020-03-31
EP3590517A1 (en) 2020-01-08
EP2854814B1 (en) 2018-01-31
ES2873949T3 (es) 2021-11-04
PT3851107T (pt) 2022-10-28
HK1208818A1 (en) 2016-03-18
PT3338781T (pt) 2019-11-29
CN104619328B (zh) 2018-10-02
PT3590517T (pt) 2021-04-07
DK3851107T3 (da) 2022-11-21
CA2872260C (en) 2020-12-22
SG11201407682TA (en) 2014-12-30
ES2665338T3 (es) 2018-04-25
NZ701469A (en) 2017-06-30
KR20150021955A (ko) 2015-03-03
DK3338781T3 (da) 2019-12-09
PH12014502584B1 (en) 2015-01-21
MY172739A (en) 2019-12-11
EP2854814A2 (en) 2015-04-08
DK2854814T3 (en) 2018-03-12
PL3590517T3 (pl) 2021-09-20
AU2013266110B2 (en) 2017-04-20
WO2013177559A2 (en) 2013-11-28
PL3851107T3 (pl) 2023-03-06
JP6172871B2 (ja) 2017-08-02
ES2753816T3 (es) 2020-04-14
IL235868A0 (en) 2015-01-29
EP2854814A4 (en) 2016-01-27
ES2930298T3 (es) 2022-12-09
CA2872260A1 (en) 2013-11-28
RU2014152625A (ru) 2016-07-20
PE20150352A1 (es) 2015-03-16
EP3851107A1 (en) 2021-07-21
HK1250014B (zh) 2020-06-12
CN104619328A (zh) 2015-05-13
DK3590517T3 (da) 2021-05-03
EP4119561A1 (en) 2023-01-18
JP2015517580A (ja) 2015-06-22
EP3338781A1 (en) 2018-06-27
EP3851107B1 (en) 2022-10-19
WO2013177559A3 (en) 2014-01-16
IL235868A (en) 2017-12-31
AU2013266110C1 (en) 2018-07-12

Similar Documents

Publication Publication Date Title
HK1250014B (zh) 雜芳基-酮稠合的氮萘烷糖皮質激素受體調節劑
ZA201604026B (en) Octahydro fused azadecalin glucocorticoid receptor modulators
HK1206332A1 (en) Liver receptor modulators
EP2609097A4 (en) AZADECALINE PYRIDYL-AMINE MODULATORS
HK1206333A1 (en) Liver receptor modulators
HK1223353A1 (zh) 受體調節劑
HK1209744A1 (en) Novel selective androgen receptor modulators
IL235557B (en) Modulators of 17 gpr receptors
EP2935284A4 (en) HETEROCYCLIC MODULATORS OF HORMONE NUCLEAR RECEPTORS
HUE038700T2 (hu) Benzofuran-2-szulfonamid származékok, mint kemokinreceptor-modulációk
EP2892527A4 (en) HETEROCYCLIC MODULATORS OF NUCLEAR HORMONAL RECEPTORS
EP2922539A4 (en) SUBSTITUTED ISOQUINOLINES USEFUL AS MODULATORS OF THE CRTH2 RECEPTOR